RAPP
Rapport Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website rapportrx.com
- Employees(FY) 58
- ISIN US75383L1026
Performance
-2.48%
1W
+28.79%
1M
+6.97%
3M
+13.56%
6M
+13.56%
YTD
+13.56%
1Y
Profile
Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Recent News & Updates
- 2024-11-04 07:00
- 2024-11-03 18:00
- 2024-09-05 07:00
- 2024-09-04 19:00
- 2024-08-29 07:00
- 2024-08-28 19:00
- 2024-08-08 07:00
- 2024-08-07 19:00
- 2024-08-06 06:30
- 2024-07-29 07:00
- 2024-07-28 19:00
- 2024-07-05 02:22
- 2024-06-12 16:01
- 2024-06-12 04:01
- 2024-06-06 18:54
Page 1 of 1
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.